Arbutus Biopharma Files 8-K, Changes Address

Ticker: ABUS · Form: 8-K · Filed: 2024-06-06T00:00:00.000Z

Sentiment: neutral

Topics: administrative, address-change

Related Tickers: ABUS

TL;DR

Arbutus Biopharma (ABUS) moved its HQ to PA, formerly Tekmira.

AI Summary

Arbutus Biopharma Corporation filed an 8-K on June 6, 2024, to report other events and financial statements. The filing indicates a change in the company's principal executive offices to 701 Veterans Circle, Warminster, Pennsylvania, 18974. The company was formerly known as Tekmira Pharmaceuticals Corp.

Why It Matters

This filing updates the company's principal executive office location, which is important for official correspondence and regulatory purposes.

Risk Assessment

Risk Level: low — This is a routine administrative filing regarding a change of address and historical company name information.

Key Players & Entities

FAQ

What is the new principal executive office address for Arbutus Biopharma Corporation?

The new principal executive office address is 701 Veterans Circle, Warminster, Pennsylvania, 18974.

When was the report filed?

The report was filed on June 6, 2024.

What was Arbutus Biopharma Corporation's former name?

Arbutus Biopharma Corporation was formerly known as Tekmira Pharmaceuticals Corp.

What is the company's state of incorporation?

The company is incorporated in British Columbia, Canada.

What is the company's IRS Employer Identification Number?

The company's IRS Employer Identification Number is 98-0597776.

From the Filing

0001171843-24-003323.txt : 20240606 0001171843-24-003323.hdr.sgml : 20240606 20240606111615 ACCESSION NUMBER: 0001171843-24-003323 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 42 CONFORMED PERIOD OF REPORT: 20240606 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240606 DATE AS OF CHANGE: 20240606 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Arbutus Biopharma Corp CENTRAL INDEX KEY: 0001447028 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 980597776 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34949 FILM NUMBER: 241024239 BUSINESS ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 BUSINESS PHONE: 604-419-3200 MAIL ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS Corp DATE OF NAME CHANGE: 20110607 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20081003 8-K 1 f8k_060524.htm FORM 8-K Form 8-K 0001447028 False 0001447028 2024-06-06 2024-06-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________ FORM 8-K _________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):  June 6, 2024 _______________________________ Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) _______________________________ British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 701 Veterans Circle Warminster , Pennsylvania 18974 (Address of Principal Executive Offices) (Zip Code) ( 267 ) 469-0914 (Registrant's telephone number, including area code)   (Former name or former address, if changed since last report) _______________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Shares, without par value ABUS The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐     Item 8.01. Other Events. On June 6, 2024, Arbutus Biopharma Corporation (“Arbutus” or the “Company”) issued a press release announcing new preliminary end-of-treatment (EOT) data from the Phase 2a clinical trial (IM-PROVE II, AB-729-202) in patients receiving ongoing standard-of-care nucleos(t)ide analogue (NA) therapy indicating that treatment with imdusiran, Arbutus’ RNAi therapeutic, followed by Barinthus Biotherapeutic's T-cell stimulating immunotherapeutic, VTP-300,  was generally safe

View on Read The Filing